Skip to main content
SVBI logo

SVBI — Investor Relations & Filings

Ticker · 1786 ISIN · TW0001786002 TW Manufacturing
Open in API
Filings indexed 1,687 across all filing types
Latest filing 2024-04-09 Regulatory Filings
Country TW Taiwan
Listing TW 1786

About SVBI

www.scivision.com.tw

SciVision Biotech Inc. is a specialized developer and manufacturer of advanced medical devices, focusing on the research and production of hyaluronic acid (HA) products. The company leverages its proprietary Crosslinked Hyaluronic Acid Platform (CHAP) technology to create high-performance solutions across multiple medical disciplines. Its core product portfolio includes subcutaneous fillers for facial aesthetics, intra-articular injections for orthopedic joint care, anti-adhesion gels for surgical applications, and vesical instillation solutions for urological treatments. By integrating specialized R&D capabilities with precision manufacturing, SciVision Biotech provides medical-grade HA applications designed to improve patient outcomes in aesthetics and therapeutic recovery. The company is committed to scientific innovation and the expansion of its patented technology to meet diverse clinical needs in the global healthcare market.

Recent filings

Filing Released Lang Actions
113年3月背書保證與資金貸與
Regulatory Filings Classification · 95% confidence The document is a brief financial disclosure from a listed company, 科妍, reporting on the status of fund loans and endorsement guarantees for the current and previous month, with zero balances and no guarantees. It contains no detailed financial statements, no management discussion, no voting results, no legal or regulatory announcements, and no mention of any meetings or reports. The content is a regulatory disclosure of financial status related to guarantees and loans, typical of a general regulatory announcement. The document length is very short (601 characters), and it does not present a full report or detailed financial data. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory disclosures that do not fit other specific categories.
2024-04-09 Chinese
113年3月營業收入
Regulatory Filings Classification · 95% confidence The document is a revenue summary report for a company named 科妍, showing monthly and cumulative net operating revenue figures with percentage changes and explanations. It is very short (785 characters) and contains no detailed financial statements or comprehensive analysis. It is a brief financial data disclosure, typical of a regulatory announcement or a summary report rather than a full financial report like an Annual Report (10-K) or Interim Report (IR). There is no indication of a meeting, voting results, management changes, or legal matters. The document is best classified as a Regulatory Filing (RNS) because it provides a regulatory disclosure of financial data without constituting a full report or presentation.
2024-04-09 Chinese
公告本公司刺激自體膠原蛋白增生皮下填補劑產品可麗媞植 入劑取得中華民國衛生福利部(TFDA)核發第三類醫材銷售許可證
Regulatory Filings Classification · 95% confidence The document is a short announcement (871 characters) from a company named 科妍生物科技股份有限公司 about obtaining a medical device sales permit from the Taiwan FDA (TFDA) for a collagen-stimulating subcutaneous filler product. It is a regulatory announcement about a product approval and does not contain financial data, management discussion, or detailed financial results. It is not a report, earnings release, or management report. It is a regulatory filing informing the market of a material event related to product approval, which could impact shareholder value. Given the short length and nature of the content, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2024-04-09 Chinese
113年03月內部人持股異動(事後)
Director's Dealing Classification · 95% confidence The document contains detailed tables listing shareholdings of company insiders, including directors, managers, and their family members. It shows changes in share ownership, including increases and decreases, and categorizes shares by type and status. This type of document is typically a Director's Dealing report, which discloses personal share transactions by company directors and executives. There is no indication of it being a full financial report, earnings release, or other types of filings. The document length is sufficient and the content is focused on insider shareholdings and transactions, matching the definition of Director's Dealing (DIRS).
2024-04-08 Chinese
113年03月董事會成員及持股
Director's Dealing Classification · 95% confidence The document is a detailed tabulation of shareholdings and pledged shares by company insiders, including directors and senior management. It lists individual holdings, pledged shares, and related percentages. The content focuses on insider share transactions and holdings rather than financial results, management changes, or regulatory announcements. There is no indication of a report publication, earnings release, or management discussion. The document is a typical insider shareholding disclosure, which corresponds to Director's Dealing filings reporting personal share transactions by company directors and executives.
2024-04-08 Chinese
本公司受邀參加統一綜合證券舉辦之法人說明會
Investor Presentation Classification · 90% confidence The document is a brief announcement about the company (1786 科妍) being invited to participate in an investor presentation hosted by a securities firm. It includes details such as the date, time, and location of the event, and mentions that full financial information can be found elsewhere. The document is short (640 characters) and does not contain any financial statements or detailed analysis. It is clearly an announcement of an upcoming investor presentation rather than the presentation itself or a financial report. Therefore, it fits the category of Investor Presentation (IP) as it relates to a presentation for investors focusing on financials and strategy, but since it is an announcement of the event, it is best classified as Regulatory Filings (RNS) because it does not contain the actual presentation content. However, given the definitions, the document is best classified as Investor Presentation (IP) because it is about the investor presentation event itself, not just a general regulatory filing. Confidence is high due to clear keywords like '法人說明會' (investor presentation) and detailed event info.
2024-04-02 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.